Clinical Trials List
2025-07-15 - 2030-12-31
Phase II
Recruiting3
ICD-10C69.40
Malignant neoplasm of unspecified ciliary body
ICD-10C69.41
Malignant neoplasm of right ciliary body
ICD-10C69.42
Malignant neoplasm of left ciliary body
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9190.0
Malignant neoplasm of eyeball, except conjunctiva, cornea, retina and choroid
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/05/01
Investigators and Locations
Co-Principal Investigator
- Chun-Hui Lee Division of Hematology & Oncology
- 魏慈慧 Division of General Surgery
- Zhu-Jun Loh Division of General Surgery
- 楊舜如 Division of Hematology & Oncology
- Shang-Hung Chen Division of Hematology & Oncology
- 黃怡菁 Division of Hematology & Oncology
- Jui-Hung Tsai Division of Hematology & Oncology
- Kuo-Ting Lee Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 呂亭芳 Division of Obstetrics & Gynecology
- 范鈞婷 Division of Obstetrics & Gynecology
- 劉芝谷 Division of Obstetrics & Gynecology
- 王韶靖 Division of Obstetrics & Gynecology
- 孫珞 Division of Obstetrics & Gynecology
- 吳振豪 Division of Radiology
- 黃曉峰 Division of Obstetrics & Gynecology
- 許世典 Division of Obstetrics & Gynecology
- 石宇翔 Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
約19 participants
-
Global
約250 participants
